Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, Neil E Kay, Nishitha M Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike Hamblin Show all
Clinical Lymphoma, Myeloma and Leukemia | CIG MEDIA GROUP, LP | Published : 2018
BACKGROUND: Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). PATIENTS AND METHODS: Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resour..View full abstract
Awarded by National Institutes of Health/National Center for Advancing Translational Sciences
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
The authors would like to thank the patients who participated in the study and their supportive families, and the investigators and clinical research staff from the study centers. This study was sponsored by Pharmacyclics LLC, an AbbVie Company. Jacqueline Barrientos's work is supported in part by National Institutes of Health/National Center for Advancing Translational Sciences (grant #UL1TR00457) and the 2015 American Society of HematologyeHarold Amos Medical Faculty Development Program fellowship. Clara Plascencia assisted with collection of data. Editorial support was provided by Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.